Drug Sponsors

Telormedix receives E.U. funding for Psoriasis treatment

Tuesday, August 13, 2013 09:00 AM

Telormedix, a clinical stage biopharmaceutical company focused on toll-like receptor 7 (TLR7) small molecules in the treatment of cancer and inflammatory diseases, has raised funding from the European Eurostars Program to coordinate an international research project involving a consortium of companies aimed at developing new formulations of one of the company’s drug candidates, TMX-302, for the treatment of psoriasis.

More... »

Eli Lilly, TVM fund invests in Ixchelsis

Friday, August 9, 2013 01:14 PM

TVM Life Science Ventures VII, a collaboration between TVM and Eli Lilly to provide venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries, has announced the fund’s second investment in Ixchelsis, a clinical-stage biotechnology startup in the U.K. Ixchelsis plans to develop to proof-of-concept IX-01, an investigational compound, originally discovered at Pfizer’s U.K. R&D site, with the potential to treat the male sexual health indication premature ejaculation.

More... »

GSK launches Action Potential Venture Capital for R&D

Friday, August 9, 2013 01:11 PM

GlaxoSmithKline has announced the launch of Cambridge, Mass.-based Action Potential Venture Capital (APVC), a $50 million strategic venture capital fund that will invest in companies that pioneer bioelectronic medicines and technologies.

More... »

Gene by Gene acquires Arpeggi

Wednesday, August 7, 2013 02:18 PM

Gene by Gene, which develops consumer DNA testing products for ancestry and genealogy applications, has acquired Arpeggi, a developer of solutions for genome sequencing, data management and computational analysis.

More... »

The Medicines Company completes Profibrix acquisition on positive trial results

Wednesday, August 7, 2013 11:53 AM

The Medicines Company announced the results of a phase III clinical trial of ProFibrix's lead biologic, Fibrocaps, and, based on its review of those results, completed its previously announced purchase of the company.

More... »

Komtur Pharmaceuticals forms joint venture with HenHeKangJain China

Wednesday, August 7, 2013 11:38 AM

Komtur Pharmaceuticals, a German specialist in clinical trial sourcing, is investing in Chinese HengHeKangJian Pharmaceutical Trading. The joint venture company will operate under Komtur-Solin Pharmaceuticals.

More... »

NuMe Health becomes MicroBiome Therapeutics

Wednesday, August 7, 2013 11:36 AM

NuMe Health has changed its name to MicroBiome Therapeutics and has hired Steve Orndorff, Ph.D., as chief executive officer.

More... »

SAGE Therapeutics awarded NIH grant for Fragile X Syndrome

Thursday, August 1, 2013 10:30 AM

The NIH has granted SAGE Therapeutics, a neuroscience product-focused company creating novel medicines to treat central nervous system (CNS) disorders, an award potentially worth up to $10 million to support the company's development of a novel drug which could be used to treat anxiety and social deficits in patients with Fragile X Syndrome (FXS).

More... »

Actelion to acquire Ceptaris

Thursday, August 1, 2013 10:00 AM

San Francisco, Calif.-based pharmaceutical company Actelion will acquire Ceptaris Therapeutics, contingent upon certain closing conditions, including FDA approval of Ceptaris' product, VALCHLOR.

More... »

Cubist to acquire Optimer, Trius

Wednesday, July 31, 2013 11:43 AM

Cubist Pharmaceuticals has signed agreements to acquire both Optimer Pharmaceuticals and Trius Therapeutics. Both transactions have been approved by company boards of directors and are expected to close later this year, subject to stockholder approval.

More... »